论文部分内容阅读
环磷酰胺是非霍奇金淋巴瘤(NHL)治疗中的关键性药物,为探讨其剂量加大的可能性,作者在给NHL患者配合使用重组人粒细胞集落刺激因子(rhG-CSF)的同时,开始了逐渐提高CHOP(环磷酰胺、阿霉素、长春新碱及强的松)方案中环磷酰胺剂量的研究。 患者与方法 27例未曾治疗或3个月内未用化疗或放疗的NHL患者,年龄均小于76岁,功能
Cyclophosphamide is a key drug in the treatment of non-Hodgkin’s lymphoma (NHL). To investigate the possibility of increased doses, the authors used recombinant human granulocyte colony-stimulating factor (rhG-CSF) in combination with NHL patients. The study of the dose of cyclophosphamide in the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen was gradually started. Patients and Methods Twenty-seven NHL patients who had not been treated or who had not used chemotherapy or radiotherapy within 3 months were younger than 76 years old.